Opportunities and Challenges in Tumor Angiogenesis Research. Back and Forth Between Bench and Bed

Advances in Cancer Research

Volumn 113, Issue , 2012, Pages 191-239

  Qin, Li ^a,b   Bromberg White, Jennifer L ^c   Qian, Chao Nan ^a,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Microvessels; Tumor vasculature; Tumor derived endothelial cells; Vasculogenesis

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CD31 ANTIGEN; CYTOTOXIC AGENT; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FORETINIB; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY DC101; NITRIC OXIDE; NOTCH RECEPTOR; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAPAMYCIN; REGN 421; SCATTER FACTOR RECEPTOR; SELUMETINIB; SEMAXANIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; XL 18;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; COLORECTAL CANCER; DRUG TREATMENT FAILURE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CARCINOMA; PATIENT SELECTION; PERICYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENTINEL LYMPH NODE; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84858376938     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394280-7.00006-3     Document Type: Chapter

References (321)

1. Akino T., Hida K., Hida Y., et al. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am. J. Pathol. 2009, 175:2657-2667.
2. Alvarez R.H., Valero V., Hortobagyi G.N. Emerging targeted therapies for breast cancer. J. Clin. Oncol. 2010, 28:3366-3379.
3. Aprahamian M., Bour G., Akladios C.Y., et al. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1alpha suppression and eradication of early hepatoma tumors in rats. Chembiochem 2011, 12:777-783.
4. Autiero M., Waltenberger J., Communi D., et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 2003, 9:936-943.
5. Baeten C.I., Hillen F., Pauwels P., de Bruine A.P., Baeten C.G. Prognostic role of vasculogenic mimicry in colorectal cancer. Dis. Colon Rectum 2009, 52:2028-2035.
6. Baluk P., Hashizume H., McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 2005, 15:102-111.
7. Bardelli A., Ponzetto C., Comoglio P.M. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. J. Biotechnol. 1994, 37:109-122.
8. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
9. Beaumont J.L., Butt Z., Baladi J., et al. Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist 2011, 16:632-640.
10. Bellmunt J., Gonzalez-Larriba J.L., Prior C., et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann. Oncol. 2011, 22:2646-2653.
11. Benton G., George J., Kleinman H.K., Arnaoutova I.P. Advancing science and technology via 3D culture on basement membrane matrix. J. Cell. Physiol. 2009, 221:18-25.
12. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
13. Berthod F., Germain L., Tremblay N., Auger F.A. Extracellular matrix deposition by fibroblasts is necessary to promote capillary-like tube formation in vitro. J. Cell. Physiol. 2006, 207:491-498.
14. Bielenberg D.R., Klagsbrun M. Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev. 2007, 26:421-431.
15. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
16. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407.
17. Bogdanovic E., Nguyen V.P., Dumont D.J. Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization. J. Cell Sci. 2006, 119:3551-3560.
18. Boneberg E.M., Legler D.F., Hoefer M.M., et al. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br. J. Cancer 2009, 101:605-614.
19. Bossi P., Viale G., Lee A.K., Alfano R., Coggi G., Bosari S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 1995, 55:5049-5053.
20. Bracarda S., Bellmunt J., Melichar B., et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011, 107:214-219.
21. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia and cancer. J. Mol. Med. 2007, 85:1301-1307.
22. Brem S., Cotran R., Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J. Natl. Cancer Inst. 1972, 48:347-356.
23. Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
24. Bucci M., Roviezzo F., Posadas I., et al. Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:904-908.
25. Busam K.J., Berwick M., Blessing K., et al. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am. J. Pathol. 1995, 147:1049-1056.
26. Bussolati B., Deambrosis I., Russo S., Deregibus M.C., Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 2003, 17:1159-1161.
27. Bussolati B., Grange C., Bruno S., et al. Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. Exp. Cell Res. 2006, 312:913-924.
28. Cacheux W., Boisserie T., Staudacher L., et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann. Oncol. 2008, 19:1659-1661.
29. Cantu De Leon D., Lopez-Graniel C., Frias Mendivil M., Chanona Vilchis G., Gomez C., De La Garza Salazar J. Significance of microvascular density (MVD) in cervical cancer recurrence. Int. J. Gynecol. Cancer 2003, 13:856-862.
30. Cao Y. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?. Int. J. Dev. Biol. 2011, 55:557-562.
31. Cao R., Brakenhielm E., Li X., et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J. 2002, 16:1575-1583.
32. Cao Y., Cao R., Hedlund E.M. Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J. Mol. Med. (Berl.) 2008, 86:785-789.
33. Cao Y., Cao R., Hedlund E.M. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J. Mol. Med. 2008, 86:785-789.
34. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
35. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
36. Castets M., Mehlen P. Netrin-1 role in angiogenesis: to be or not to be a pro-angiogenic factor?. Cell Cycle 2010, 9:1466-1471.
37. Cernea C.R., Ferraz A.R., de Castro I.V., et al. Angiogenesis and skin carcinomas with skull base invasion: a case-control study. Head Neck 2004, 26:396-400.
38. Chamberlain M.C. Bevacizumab for the treatment of recurrent glioblastoma. Clin. Med. Insights Oncol. 2011, 5:117-129.
39. Chandrachud L.M., Pendleton N., Chisholm D.M., Horan M.A., Schor A.M. Relationship between vascularity, age and survival in non-small-cell lung cancer. Br. J. Cancer 1997, 76:1367-1375.
40. Charalambous C., Pen L.B., Su Y.S., Milan J., Chen T.C., Hofman F.M. Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. Cancer Res. 2005, 65:10347-10354.
41. Chen J.A., Shi M., Li J.Q., Qian C.N. Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol. Int. 2010, 4:537-547.
42. Chen H.T., Cai Q.C., Zheng J.M., et al. High Expression of Delta-Like Ligand 4 Predicts Poor Prognosis After Curative Resection for Pancreatic Cancer. Ann. Surg. Oncol. 2011, [Epub ahead of print].
43. Chen Z.Y., Wei W., Guo Z.X., Lin J.R., Shi M., Guo R.P. Morphologic classification of microvessels in hepatocellular carcinoma is associated with the prognosis after resection. J. Gastroenterol. Hepatol. 2011, 26:866-874.
44. Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics 2010, 4:91-101.
45. Couvelard A., O'Toole D., Turley H., et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 2005, 92:94-101.
46. Crawford Y., Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol. Sci. 2009, 30:624-630.
47. Cross M.J., Hodgkin M.N., Roberts S., Landgren E., Wakelam M.J., Claesson-Welsh L. Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells. J. Cell Sci. 2000, 113(Pt. 4):643-651.
48. Czubayko F., Liaudet-Coopman E.D., Aigner A., Tuveson A.T., Berchem G.J., Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat. Med. 1997, 3:1137-1140.
49. D'Agostino R.B. Changing end points in breast-cancer drug approval-the Avastin story. N. Engl. J. Med. 2011, 365:e2.
50. Das B., Yeger H., Tsuchida R., et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res. 2005, 65:7267-7275.
51. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97:1093-1107.
52. Davis S., Aldrich T.H., Jones P.F., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
53. de Groot J.F., Lamborn K.R., Chang S.M., et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 2011, 29:2689-2695.
54. De Smet F., Segura I., De Bock K., Hohensinner P.J., Carmeliet P. Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler. Thromb. Vasc. Biol. 2009, 29:639-649.
55. Del Bufalo D., Ciuffreda L., Trisciuoglio D., et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006, 66:5549-5554.
56. Desar I.M., van Herpen C.M., van Laarhoven H.W., Barentsz J.O., Oyen W.J., van der Graaf W.T. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat. Rev. 2009, 35:309-321.
57. Dickinson A.J., Fox S.B., Persad R.A., Hollyer J., Sibley G.N., Harris A.L. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol. 1994, 74:762-766.
58. Diez H., Fischer A., Winkler A., et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp. Cell Res. 2007, 313:1-9.
59. Dimmeler S., Zeiher A.M. Nitric oxide-an endothelial cell survival factor. Cell Death Differ. 1999, 6:964-968.
60. Ding Y.T., Kumar S., Yu D.C. The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology 2008, 75:265-273.
61. Ding T., Xu J., Wang F., et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 2009, 40:381-389.
62. Ding T., Xu J., Zhang Y., et al. Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer 2011, 117:4878-4889.
63. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 2006, 80:1183-1196.
64. Dome B., Paku S., Somlai B., Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J. Pathol. 2002, 197:355-362.
65. Dowling R.J., Topisirovic I., Fonseca B.D., Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 2010, 1804:433-439.
66. Duarte C.D., Greferath R., Nicolau C., Lehn J.M. myo-Inositol trispyrophosphate: a novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane. Chembiochem 2010, 11:2543-2548.
67. Duda D.G., Jain R.K., Willett C.G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 2007, 25:4033-4042.
68. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8:210-221.
69. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
70. Eichmann A., Le Noble F., Autiero M., Carmeliet P. Guidance of vascular and neural network formation. Curr. Opin. Neurobiol. 2005, 15:108-115.
71. El-Assal O.N., Yamanoi A., Soda Y., et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998, 27:1554-1562.
72. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
73. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
74. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
75. Falcon B.L., Barr S., Gokhale P.C., et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res. 2011, 71:1573-1583.
76. Farnsworth R.H., Karnezis T., Shayan R., et al. A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth. Cancer Res. 2011, 71:6547-6557.
77. Fernandez-Aguilar S., Jondet M., Simonart T., Noel J.C. Microvessel and lymphatic density in tubular carcinoma of the breast: comparative study with invasive low-grade ductal carcinoma. Breast 2006, 15:782-785.
78. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
79. Fett J.W., Strydom D.J., Lobb R.R., et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985, 24:5480-5486.
80. Fogg V.C., Lanning N.J., Mackeigan J.P. Mitochondria in cancer: at the crossroads of life and death. Chin. J. Cancer 2011, 30:526-539.
81. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
82. Foss A.J., Alexander R.A., Jefferies L.W., Hungerford J.L., Harris A.L., Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996, 56:2900-2903.
83. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15:197-204.
84. Fujiwara T., Fukushi J., Yamamoto S., et al. Macrophage infiltration predicts a poor prognosis for human Ewing sarcoma. Am. J. Pathol. 2011, 179:1157-1170.
85. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6:521-534.
86. Gaitskell K., Martinek I., Bryant A., Kehoe S., Nicum S., Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst. Rev. 2011, 9:CD007930.
87. Gandino L., Longati P., Medico E., Prat M., Comoglio P.M. Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J. Biol. Chem. 1994, 269:1815-1820.
88. Gao X., Xu Z. Mechanisms of action of angiogenin. Acta. Biochim. Biophys. Sin. (Shanghai) 2008, 40:619-624.
89. Garcia S., Dales J.P., Charafe-Jauffret E., et al. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int. J. Oncol. 2007, 31:49-58.
90. Gasparini G., Weidner N., Bevilacqua P., et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol. 1994, 12:454-466.
91. Gee M.S., Procopio W.N., Makonnen S., Feldman M.D., Yeilding N.M., Lee W.M. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol. 2003, 162:183-193.
92. George S., Shah S.N., Bukowski R.M. Stable disease in renal cell carcinoma after using signal transduction inhibitors. Rev. Recent Clin. Trials 2011, 5:117-122.
93. Ghosh K., Thodeti C.K., Dudley A.C., Mammoto A., Klagsbrun M., Ingber D.E. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc. Natl. Acad. Sci. USA 2008, 105:11305-11310.
94. Giordano F.J., Johnson R.S. Angiogenesis: the role of the microenvironment in flipping the switch. Curr. Opin. Genet. Dev. 2001, 11:35-40.
95. Giridharan W., Hughes J., Fenton J.E., Jones A.S. Lymph node metastases in the lower neck. Clin. Otolaryngol. Allied Sci. 2003, 28:221-226.
96. Girouard S.D., Murphy G.F. Melanoma stem cells: not rare, but well done. Lab. Invest. 2011, 91:647-664.
97. Gordon M.S. Antiangiogenic therapies: is VEGF-A inhibition alone enough?. Expert Rev. Anticancer Ther. 2011, 11:485-496.
98. Grepin R., Guyot M., Jacquin M., et al. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: The role of CXCL cytokines. Oncogene 2011, 206:1-12.
99. Grose R., Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005, 16:179-186.
100. Guan Z.Z., Xu J.M., Luo R.C., et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin. J. Cancer 2011, 30:682-689.
101. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
102. Hallmann R., Horn N., Selg M., Wendler O., Pausch F., Sorokin L.M. Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 2005, 85:979-1000.
103. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
104. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
105. Hasina R., Whipple M.E., Martin L.E., Kuo W.P., Ohno-Machado L., Lingen M.W. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab. Invest. 2008, 88:342-353.
106. Heldin C.H., Ostman A., Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1998, 1378:F79-F113.
107. Helfrich I., Schadendorf D. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?. Mol. Oncol. 2011, 5:137-149.
108. Helfrich I., Scheffrahn I., Bartling S., et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J. Exp. Med. 2010, 207:491-503.
109. Hellstrom M., Kalen M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
110. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
111. Hess A.R., Seftor E.A., Gruman L.M., Kinch M.S., Seftor R.E., Hendrix M.J. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol. Ther. 2006, 5:228-233.
112. Hida K., Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005, 65:2507-2510.
113. Hida K., Hida Y., Amin D.N., et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004, 64:8249-8255.
114. Hillen F., Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007, 26:489-502.
115. Hillen F., van de Winkel A., Creytens D., Vermeulen A.H., Griffioen A.W. Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res. 2006, 16:453-457.
116. Hirschi K.K., D'Amore P.A. Pericytes in the microvasculature. Cardiovasc. Res. 1996, 32:687-698.
117. Hlushchuk R., Riesterer O., Baum O., et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am. J. Pathol. 2008, 173:1173-1185.
118. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93:266-276.
119. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
120. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 2002, 99:11393-11398.
121. Hood J.D., Meininger C.J., Ziche M., Granger H.J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 1998, 274:H1054-H1058.
122. Horak E.R., Leek R., Klenk N., et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992, 340:1120-1124.
123. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991, 5:1806-1814.
124. Hu B., Cheng S.Y. Angiopoietin-2: development of inhibitors for cancer therapy. Curr. Oncol. Rep. 2009, 11:111-116.
125. Hu W., Lu C., Han H.D., et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011, 71:6030-6039.
126. Huang S., Pettaway C.A., Uehara H., Bucana C.D., Fidler I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001, 20:4188-4197.
127. Huang J., Bae J.O., Tsai J.P., et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int. J. Oncol. 2009, 34:79-87.
128. Huang D., Ding Y., Zhou M., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010, 70:1063-1071.
129. Huang D., Ding Y., Li Y., et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010, 70:1053-1062.
130. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22:7004-7014.
131. Huminiecki L., Bicknell R. In silico cloning of novel endothelial-specific genes. Genome Res. 2000, 10:1796-1806.
132. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
133. Ibaragi S., Yoshioka N., Kishikawa H., et al. Angiogenin-stimulated rRNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia. Mol. Cancer Res. 2009, 7:415-424.
134. Ide T., Kitajima Y., Miyoshi A., et al. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann. Surg. Oncol. 2007, 14:2600-2607.
135. Igarashi M., Dhar D.K., Kubota H., Yamamoto A., El-Assal O., Nagasue N. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 1998, 82:1225-1232.
136. Inai T., Mancuso M., Hashizume H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 2004, 165:35-52.
137. Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 2005, 37:19-24.
138. Iozzo R.V., Zoeller J.J., Nystrom A. Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol. Cells 2009, 27:503-513.
139. Iso T., Kedes L., Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell. Physiol. 2003, 194:237-255.
140. Iwahana M., Utoguchi N., Mayumi T., Goryo M., Okada K. Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors. Anticancer Res. 1998, 18:2977-2980.
141. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
142. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
143. Jain R.K., Duda D.G., Willett C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009, 6:327-338.
144. Jing Y., Ma N., Fan T., et al. Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor. Cancer Invest. 2011, 29:485-493.
145. Jones A., Ellis P. Potential withdrawal of bevacizumab for the treatment of breast cancer. BMJ 2011, 343:d4946.
146. Jones M.K., Tsugawa K., Tarnawski A.S., Baatar D. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem. Biophys. Res. Commun. 2004, 318:520-528.
147. Jubb A.M., Soilleux E.J., Turley H., et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am. J. Pathol. 2010, 176:2019-2028.
148. Jung Y.D., Ahmad S.A., Akagi Y., et al. Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev. 2000, 19:147-157.
149. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96:1788-1795.
150. Kamba T., Tam B.Y., Hashizume H., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H560-H576.
151. Kandel J., Bossy-Wetzel E., Radvanyi F., Klagsbrun M., Folkman J., Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66:1095-1104.
152. Kane R.C., Farrell A.T., Saber H., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 2006, 12:7271-7278.
153. Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
154. Karamouzis M.V., Moschos S.J. The use of endostatin in the treatment of solid tumors. Expert Opin. Biol. Ther. 2009, 9:641-648.
155. Katoh M. Notch signaling in gastrointestinal tract (review). Int. J. Oncol. 2007, 30:247-251.
156. Kawasaki K., Smith R.S., Hsieh C.M., Sun J., Chao J., Liao J.K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell. Biol. 2003, 23:5726-5737.
157. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70:1469-1480.
158. Kerbel R.S., Yu J., Tran J., et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001, 20:79-86.
159. Kieda C., Greferath R., Crola da Silva C., Fylaktakidou K.C., Lehn J.M., Nicolau C. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proc. Natl. Acad. Sci. USA 2006, 103:15576-15581.
160. Kienast Y., von Baumgarten L., Fuhrmann M., et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 2010, 16:116-122.
161. Kimura H., Weisz A., Kurashima Y., et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000, 95:189-197.
162. Klagsbrun M., Takashima S., Mamluk R. The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 2002, 515:33-48.
163. Knudsen B.S., Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 2008, 18:87-96.
164. Koch A.E., Polverini P.J., Kunkel S.L., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
165. Kouhara H., Hadari Y.R., Spivak-Kroizman T., et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997, 89:693-702.
166. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009, 27:740-745.
167. Kreisl T.N., Zhang W., Odia Y., et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011, 13:1143-1150.
168. Kudo M. Future treatment option for hepatocellular carcinoma: a focus on brivanib. Dig. Dis. 2011, 29:316-320.
169. Kume T. Novel insights into the differential functions of Notch ligands in vascular formation. J. Angiogenes. Res. 2009, 1:8.
170. Kusamura S., Derchain S., Alvarenga M., Gomes C.P., Syrjanen K.J., Andrade L.A. Expression of p53, c-erbB-2, Ki-67, and CD34 in granulosa cell tumor of the ovary. Int. J. Gynecol. Cancer 2003, 13:450-457.
171. Lackner C., Jukic Z., Tsybrovskyy O., et al. Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch. 2004, 445:160-167.
172. Larrivee B., Freitas C., Trombe M., et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev. 2007, 21:2433-2447.
173. Le Tourneau C., Faivre S., Serova M., Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?. Br. J. Cancer 2008, 99:1197-1203.
174. Lee C.H., Espinosa I., Vrijaldenhoven S., et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin. Cancer Res. 2008, 14:1423-1430.
175. Leenders W.P., Kusters B., de Waal R.M. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002, 9:83-87.
176. Leibovich S.J., Polverini P.J., Shepard H.M., Wiseman D.M., Shively V., Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987, 329:630-632.
177. Li M., Gu Y., Zhang Z., et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol. Oncol. Res. 2010, 16:259-266.
178. Li Y., Zhang Z.F., Chen J., et al. VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am. J. Transl. Res. 2010, 2:296-308.
179. Lim W.T., Ng Q.S., Ivy P., et al. A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin. Cancer Res. 2011, 17:5481-5489.
180. Lin A.Y., Maniotis A.J., Valyi-Nagy K., et al. Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch. Pathol. Lab. Med. 2005, 129:884-892.
181. Lin J.Y., Li X.Y., Tadashi N., Dong P. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chin. J. Cancer 2011, 30:280-286.
182. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
183. Lindmark G., Gerdin B., Sundberg C., Pahlman L., Bergstrom R., Glimelius B. Prognostic significance of the microvascular count in colorectal cancer. J. Clin. Oncol. 1996, 14:461-466.
184. Lissbrant I.F., Stattin P., Damber J.E., Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997, 33:38-45.
185. Liu C., Huang H., Donate F., et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res. 2002, 62:5470-5475.
186. Liu X.M., Zhang Q.P., Mu Y.G., et al. Clinical significance of vasculogenic mimicry in human gliomas. J. Neurooncol. 2011, 105:173-179.
187. Liu K.W., Hu B., Cheng S.Y. Platelet-derived growth factor signaling in human malignancies. Chin. J. Cancer 2011, 30:581-584.
188. Loges S., Mazzone M., Hohensinner P., Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170.
189. Longati P., Bardelli A., Ponzetto C., Naldini L., Comoglio P.M. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994, 9:49-57.
190. Lopez-Rivera E., Lizarbe T.R., Martinez-Moreno M., et al. Matrix metalloproteinase 13 mediates nitric oxide activation of endothelial cell migration. Proc. Natl. Acad. Sci. USA 2005, 102:3685-3690.
191. Maina F., Casagranda F., Audero E., et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 1996, 87:531-542.
192. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
193. Mancuso M.R., Davis R., Norberg S.M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
194. Maniotis A.J., Folberg R., Hess A., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999, 155:739-752.
195. Marioni G., Gaio E., Giacomelli L., et al. Endoglin (CD105) expression in head and neck basaloid squamous cell carcinoma. Acta Otolaryngol. 2005, 125:307-311.
196. McDonald D.M., Foss A.J. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev. 2000, 19:109-120.
197. Meier F., Will S., Ellwanger U., et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. J. Dermatol. 2002, 147:62-70.
198. Merrick D.T., Haney J., Petrunich S., et al. Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. Lung Cancer 2005, 48:31-45.
199. Miles D., Harbeck N., Escudier B., et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 2011, 29:83-88.
200. Millauer B., Wizigmann-Voos S., Schnurch H., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
201. Miller K.D., Sweeney C.J., Sledge G.W. Can tumor angiogenesis be inhibited without resistance?. EXS 2005, 94:95-112.
202. Miller C.T., Lin L., Casper A.M., et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006, 25:409-418.
203. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357:2666-2676.
204. Mooteri S., Rubin D., Leurgans S., Jakate S., Drab E., Saclarides T. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis. Colon Rectum 1996, 39:1073-1080.
205. Mumm J.S., Kopan R. Notch signaling: from the outside in. Dev. Biol. 2000, 228:151-165.
206. Nacht M., St Martin T.B., Byrne A., et al. Netrin-4 regulates angiogenic responses and tumor cell growth. Exp. Cell Res. 2009, 315:784-794.
207. Nagy J.A., Chang S.H., Shih S.C., Dvorak A.M., Dvorak H.F. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 2010, 36:321-331.
208. Neufeld G., Cohen T., Shraga N., Lange T., Kessler O., Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 2002, 12:13-19.
209. Nico B., Benagiano V., Mangieri D., Maruotti N., Vacca A., Ribatti D. Evaluation of microvascular density in tumors: pro and contra. Histol. Histopathol. 2008, 23:601-607.
210. Nissen L.J., Cao R., Hedlund E.M., et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 2007, 117:2766-2777.
211. Noguera-Troise I., Daly C., Papadopoulos N.J., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found. Symp. 2007, 283:106-120. discussion 21-5, 238-41.
212. North S., Moenner M., Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett. 2005, 218:1-14.
213. Nowak D.G., Amin E.M., Rennel E.S., et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms-a novel therapeutic strategy for angiogenesis. J. Biol. Chem. 2010, 285:5532-5540.
214. O'Keeffe M.B., Devlin A.H., Burns A.J., et al. Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol. Res. 2008, 17:93-101.
215. Oliveira C.J., Schindler F., Ventura A.M., et al. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic. Biol. Med. 2003, 35:381-396.
216. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
217. Ong S.H., Guy G.R., Hadari Y.R., et al. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol. Cell. Biol. 2000, 20:979-989.
218. Onimaru Y., Tsukasaki K., Murata K., et al. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int. J. Oncol. 2008, 33:697-703.
219. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
220. Otsuka T., Takayama H., Sharp R., et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998, 58:5157-5167.
221. Oudard S., Beuselinck B., Decoene J., Albers P. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat. Rev. 2011, 37:178-184.
222. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
223. Passalidou E., Trivella M., Singh N., et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br. J. Cancer 2002, 86:244-249.
224. Patel N.S., Li J.L., Generali D., Poulsom R., Cranston D.W., Harris A.L. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005, 65:8690-8697.
225. Patel N.S., Dobbie M.S., Rochester M., et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res. 2006, 12:4836-4844.
226. Peghini P.L., Iwamoto M., Raffeld M., et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin. Cancer Res. 2002, 8:2273-2285.
227. Peng F., Chen M. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia. Chin. J. Cancer 2010, 29:715-720.
228. Peschard P., Ishiyama N., Lin T., Lipkowitz S., Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 2004, 279:29565-29571.
229. Pezzella F., Pastorino U., Tagliabue E., et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 1997, 151:1417-1423.
230. Pfander D., Swoboda B., Cramer T. The role of HIF-1alpha in maintaining cartilage homeostasis and during the pathogenesis of osteoarthritis. Arthritis Res. Ther. 2006, 8:104.
231. Polak P., Hall M.N. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol. 2009, 21:209-218.
232. Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J. Steroid Biochem. Mol. Biol. 2008, 108:261-266.
233. Ponzetto C., Bardelli A., Zhen Z., et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994, 77:261-271.
234. Primo L., Seano G., Roca C., et al. Increased expression of alpha6 integrin in endothelial cells unveils a proangiogenic role for basement membrane. Cancer Res. 2010, 70:5759-5769.
235. Qian C.N., Min H.Q., Liang X.M., Zheng S.S., Lin H.L. Primary study of neovasculature correlating with metastatic nasopharyngeal carcinoma using computer image analysis. J. Cancer Res. Clin. Oncol. 1997, 123:645-651.
236. Qian C.N., Guo X., Cao B., et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 2002, 62:589-596.
237. Qian C.N., Berghuis B., Tsarfaty G., et al. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 2006, 66:10365-10376.
238. Qian C.N., Resau J.H., Teh B.T. Prospects for vasculature reorganization in sentinel lymph nodes. Cell Cycle 2007, 6:514-517.
239. Qian C.N., Huang D., Wondergem B., Teh B.T. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer 2009, 115:2282-2289.
240. Randall L.M., Monk B.J. Bevacizumab toxicities and their management in ovarian cancer. Gynecol. Oncol. 2010, 117:497-504.
241. Randall L.M., Monk B.J. Bevacizumab toxicities and their management in ovarian cancer. Gynecol. Oncol. 2011, 117:497-504.
242. Ratcliffe P.J. HIF-1 and HIF-2: working alone or together in hypoxia?. J. Clin. Invest. 2007, 117:862-865.
243. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364:501-513.
244. Ribatti D., Ponzoni M. Antiangiogenic strategies in neuroblastoma. Cancer Treat. Rev. 2005, 31:27-34.
245. Ricci-Vitiani L., Pallini R., Biffoni M., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
246. Ridgway J., Zhang G., Wu Y., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
247. Ridnour L.A., Isenberg J.S., Espey M.G., Thomas D.D., Roberts D.D., Wink D.A. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc. Natl. Acad. Sci. USA 2005, 102:13147-13152.
248. Roberts D.D., Isenberg J.S., Ridnour L.A., Wink D.A. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin. Cancer Res. 2007, 13:795-798.
249. Roca C., Adams R.H. Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 2007, 21:2511-2524.
250. Sackstein R. Physiologic migration of lymphocytes to lymph nodes following bone marrow transplantation: role in immune recovery. Semin. Oncol. 1993, 20:34-39.
251. Samant R.S., Shevde L.A. Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2011, 2:122-134.
252. Sanchez-Solana B., Nueda M.L., Ruvira M.D., et al. The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities. Biochim. Biophys. Acta 2011, 1813:1153-1164.
253. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
254. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
255. Sasaki T., Hohenester E., Timpl R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life 2002, 53:77-84.
256. Schmedtje J.F., Ji Y.S., Liu W.L., DuBois R.N., Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 1997, 272:601-608.
257. Schmidt D., Textor B., Pein O.T., et al. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J. 2007, 26:710-719.
258. Schneider B.P., Sledge G.W. Drug insight: VEGF as a therapeutic target for breast cancer. Nat. Clin. Pract. Oncol. 2007, 4:181-189.
259. Schraufstatter I.U., Chung J., Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L1094-L1103.
260. Schutz F.A., Jardim D.L., Je Y., Choueiri T.K. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur. J. Cancer 2011, 47:1161-1174.
261. Seifert R.A., Hart C.E., Phillips P.E., et al. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J. Biol. Chem. 1989, 264:8771-8778.
262. Semenza G.L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107:1-3.
263. Sharma N., Seftor R.E., Seftor E.A., et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002, 50:189-201.
264. Sheth P.R., Hays J.L., Elferink L.A., Watowich S.J. Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation. Biochemistry 2008, 47:4028-4038.
265. Shimizu T., Hino K., Tauchi K., Ansai Y., Tsukada K. Predication of axillary lymph node metastasis by intravenous digital subtraction angiography in breast cancer, its correlation with microvascular density. Breast Cancer Res. Treat. 2000, 61:261-269.
266. Shimoyama S., Kaminishi M. Increased angiogenin expression in gastric cancer correlated with cancer progression. J. Cancer Res. Clin. Oncol. 2000, 126:468-474.
267. Shirakawa K., Wakasugi H., Heike Y., et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int. J. Cancer 2002, 99:821-828.
268. Shojaei F., Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J. 2007, 13:345-348.
269. Shojaei F., Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat. 2008, 11:219-230.
270. Shojaei F., Zhong C., Wu X., Yu L., Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol. 2008, 18:372-378.
271. Sood A.K., Fletcher M.S., Zahn C.M., et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol. Ther. 2002, 1:661-664.
272. Squadrito M.L., De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol. Aspects Med. 2011, 32:123-145.
273. Stellrecht C.M., Phillip C.J., Cervantes-Gomez F., Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 2007, 67:9913-9920.
274. Suchting S., Heal P., Tahtis K., Stewart L.M., Bicknell R. Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. FASEB J. 2005, 19:121-123.
275. Suchting S., Freitas C., le Noble F., et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. USA 2007, 104:3225-3230.
276. Summers J., Cohen M.H., Keegan P., Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2011, 15:104-111.
277. Tammela T., Enholm B., Alitalo K., Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc. Res. 2005, 65:550-563.
278. Tammela T., Zarkada G., Wallgard E., et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
279. Tang N., Wang L., Esko J., et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6:485-495.
280. Taylor C.T., Furuta G.T., Synnestvedt K., Colgan S.P. Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc. Natl. Acad. Sci. USA 2000, 97:12091-12096.
281. Taylor K.L., Henderson A.M., Hughes C.C. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc. Res. 2002, 64:372-383.
282. Teng L.S., Jin K.T., He K.F., Zhang J., Wang H.H., Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J. Chin. Med. Assoc. 2010, 73:449-456.
283. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
284. Thomas M., Augustin H.G. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009, 12:125-137.
285. Thompson W.D., Shiach K.J., Fraser R.A., McIntosh L.C., Simpson J.G. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth. J. Pathol. 1987, 151:323-332.
286. Thurston G., Kitajewski J. VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br. J. Cancer 2008, 99:1204-1209.
287. Timpl R., Sasaki T., Kostka G., Chu M.L. Fibulins: a versatile family of extracellular matrix proteins. Nat. Rev. Mol. Cell Biol. 2003, 4:479-489.
288. Vadnais J., Nault G., Daher Z., et al. Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion. J. Biol. Chem. 2002, 277:48342-48350.
289. Valenzuela D.M., Griffiths J.A., Rojas J., et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci. USA 1999, 96:1904-1909.
290. Van Meter M.E., Kim E.S. Bevacizumab: current updates in treatment. Curr. Opin. Oncol. 2011, 22:586-591.
291. Vaupel P., Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9(Suppl. 5):4-9.
292. Vaupel P., Kelleher D.K., Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 2001, 28:29-35.
293. Verma N., Swain S.M. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?. J. Clin. Oncol. 2011, 29:603-606.
294. von Andrian U.H., M'Rini C. In situ analysis of lymphocyte migration to lymph nodes. Cell Adhes. Commun. 1998, 6:85-96.
295. von Baumgarten L.D., Brucker D., Tirniceru A.L., et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin. Cancer Res. 2011, 17:6192-6205.
296. Wang R., Chadalavada K., Wilshire J., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
297. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
298. Weidner N., Folkman J., Pozza F., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992, 84:1875-1887.
299. Willett C.G., Kozin S.V., Duda D.G., et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin. Oncol. 2006, 33:S35-S40.
300. Williamson S.K., Moon J., Huang C.H., et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J. Clin. Oncol. 2010, 28:3330-3335.
301. Winkler E.A., Bell R.D., Zlokovic B.V. Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol. Neurodegener. 2010, 5:32.
302. Wojta J., Kaun C., Breuss J.M., et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab. Invest. 1999, 79:427-438.
303. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
304. Xie H., Zou L., Zhu J., Yang Y. Effects of netrin-1 and netrin-1 knockdown on human umbilical vein endothelial cells and angiogenesis of rat placenta. Placenta 2011, 32:546-553.
305. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
306. Yang X., Qiao D., Meyer K., Friedl A. Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis. Cancer Res. 2009, 69:1668-1677.
307. Yao X., Qian C.N., Zhang Z.F., et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin. Cancer Res. 2007, 13:161-169.
308. Yeh J.C., Hiraoka N., Petryniak B., et al. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase. Cell 2001, 105:957-969.
309. Yi S., Tsao M.S. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000, 2:226-234.
310. Yi S., Chen J.R., Viallet J., Schwall R.H., Nakamura T., Tsao M.S. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br. J. Cancer 1998, 77:2162-2170.
311. You W.K., McDonald D.M. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 2008, 41:833-839.
312. You W.K., Sennino B., Williamson C.W., et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011, 71:4758-4768.
313. Yu J., deMuinck E.D., Zhuang Z., et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc. Natl. Acad. Sci. USA 2005, 102:10999-11004.
314. Yurchenco P.D., Cheng Y.S. Self-assembly and calcium-binding sites in laminin. A three-arm interaction model. J. Biol. Chem. 1993, 268:17286-17299.
315. Zamora D.O., Riviere M., Choi D., et al. Proteomic profiling of human retinal and choroidal endothelial cells reveals molecular heterogeneity related to tissue of origin. Mol. Vis. 2007, 13:2058-2065.
316. Zaragoza C., Soria E., Lopez E., et al. Activation of the mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 by the nitric oxide-cGMP-cGMP-dependent protein kinase axis regulates the expression of matrix metalloproteinase 13 in vascular endothelial cells. Mol. Pharmacol. 2002, 62:927-935.
317. Zhang J., Burridge K.A., Friedman M.H. In vivo differences between endothelial transcriptional profiles of coronary and iliac arteries revealed by microarray analysis. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1556-H1561.
318. Zhao Z.S., Zhou J.L., Yao G.Y., Ru G.Q., Ma J., Ruan J. Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J. Gastroenterol. 2005, 11:3227-3233.
319. Zhao Y.Y., Xue C., Jiang W., et al. Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab. J. Thorac. Oncol. 2012, 7:71-75.
320. Zhu X.D., Zhang J.B., Zhuang P.Y., et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 2008, 26:2707-2716.
321. Zuniga R.M., Torcuator R., Jain R., et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol 2010, 99:237-242.